CLEVER LEAVES HOLDINGS INC (CLVR) Stock Fundamental Analysis

NASDAQ:CLVR • CA1867602031

3 USD
+0.89 (+42.18%)
At close: May 16, 2024
3.05 USD
+0.05 (+1.67%)
After Hours: 5/16/2024, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CLVR. CLVR was compared to 191 industry peers in the Pharmaceuticals industry. CLVR has a bad profitability rating. Also its financial health evaluation is rather negative. CLVR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CLVR has reported negative net income.
  • In the past year CLVR has reported a negative cash flow from operations.
  • In the past 5 years CLVR always reported negative net income.
  • In the past 5 years CLVR always reported negative operating cash flow.
CLVR Yearly Net Income VS EBIT VS OCF VS FCFCLVR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -57.31%, CLVR is not doing good in the industry: 62.56% of the companies in the same industry are doing better.
  • The Return On Equity of CLVR (-73.94%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -57.31%
ROE -73.94%
ROIC N/A
ROA(3y)-74.55%
ROA(5y)-49.14%
ROE(3y)-100.17%
ROE(5y)-67.74%
ROIC(3y)N/A
ROIC(5y)N/A
CLVR Yearly ROA, ROE, ROICCLVR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • CLVR's Gross Margin of 37.63% is in line compared to the rest of the industry. CLVR outperforms 56.41% of its industry peers.
  • In the last couple of years the Gross Margin of CLVR has declined.
  • CLVR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.93%
GM growth 5YN/A
CLVR Yearly Profit, Operating, Gross MarginsCLVR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • CLVR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CLVR has been increased compared to 1 year ago.
  • The debt/assets ratio for CLVR is higher compared to a year ago.
CLVR Yearly Shares OutstandingCLVR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
CLVR Yearly Total Debt VS Total AssetsCLVR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • CLVR has an Altman-Z score of -9.24. This is a bad value and indicates that CLVR is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -9.24, CLVR is not doing good in the industry: 76.41% of the companies in the same industry are doing better.
  • CLVR has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.03, CLVR is in line with its industry, outperforming 51.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -9.24
ROIC/WACCN/A
WACC10.07%
CLVR Yearly LT Debt VS Equity VS FCFCLVR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

  • CLVR has a Current Ratio of 2.40. This indicates that CLVR is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of CLVR (2.40) is worse than 60.00% of its industry peers.
  • CLVR has a Quick Ratio of 1.63. This is a normal value and indicates that CLVR is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.63, CLVR is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 1.63
CLVR Yearly Current Assets VS Current LiabilitesCLVR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 78.15% over the past year.
  • CLVR shows a small growth in Revenue. In the last year, the Revenue has grown by 4.80%.
  • Measured over the past years, CLVR shows a quite strong growth in Revenue. The Revenue has been growing by 12.85% on average per year.
EPS 1Y (TTM)78.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.01%
Revenue 1Y (TTM)4.8%
Revenue growth 3Y12.85%
Revenue growth 5YN/A
Sales Q2Q%0.61%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue is expected to grow by 128.91% on average over the next years. This is a very strong growth
EPS Next Y29.03%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50%
Revenue Next 2Y128.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLVR Yearly Revenue VS EstimatesCLVR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CLVR Yearly EPS VS EstimatesCLVR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CLVR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLVR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLVR Price Earnings VS Forward Price EarningsCLVR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLVR Per share dataCLVR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CLVR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CLEVER LEAVES HOLDINGS INC

NASDAQ:CLVR (5/16/2024, 8:00:00 PM)

After market: 3.05 +0.05 (+1.67%)

3

+0.89 (+42.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-23
Earnings (Next)08-12
Inst Owners2.55%
Inst Owner Change-22.23%
Ins Owners342.65%
Ins Owner Change0%
Market Cap5.25M
Revenue(TTM)17.42M
Net Income(TTM)-17.91M
Analysts43.33
Price Target24.48 (716%)
Short Float %0.51%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.79%
Min Revenue beat(2)-27.98%
Max Revenue beat(2)-21.6%
Revenue beat(4)1
Avg Revenue beat(4)-10.9%
Min Revenue beat(4)-27.98%
Max Revenue beat(4)8.33%
Revenue beat(8)3
Avg Revenue beat(8)-12.3%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-11.4
EYN/A
EPS(NY)-6.73
Fwd EYN/A
FCF(TTM)-6.59
FCFYN/A
OCF(TTM)-6.58
OCFYN/A
SpS9.95
BVpS13.84
TBVpS12.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -57.31%
ROE -73.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.63%
FCFM N/A
ROA(3y)-74.55%
ROA(5y)-49.14%
ROE(3y)-100.17%
ROE(5y)-67.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.93%
GM growth 5YN/A
F-Score3
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.31%
Cap/Sales 0.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 1.63
Altman-Z -9.24
F-Score3
WACC10.07%
ROIC/WACCN/A
Cap/Depr(3y)81.47%
Cap/Depr(5y)N/A
Cap/Sales(3y)18.3%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.01%
EPS Next Y29.03%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.8%
Revenue growth 3Y12.85%
Revenue growth 5YN/A
Sales Q2Q%0.61%
Revenue Next Year50%
Revenue Next 2Y128.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.41%
OCF growth 3YN/A
OCF growth 5YN/A

CLEVER LEAVES HOLDINGS INC / CLVR FAQ

What is the ChartMill fundamental rating of CLEVER LEAVES HOLDINGS INC (CLVR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CLVR.


Can you provide the valuation status for CLEVER LEAVES HOLDINGS INC?

ChartMill assigns a valuation rating of 0 / 10 to CLEVER LEAVES HOLDINGS INC (CLVR). This can be considered as Overvalued.


Can you provide the profitability details for CLEVER LEAVES HOLDINGS INC?

CLEVER LEAVES HOLDINGS INC (CLVR) has a profitability rating of 1 / 10.


What is the expected EPS growth for CLEVER LEAVES HOLDINGS INC (CLVR) stock?

The Earnings per Share (EPS) of CLEVER LEAVES HOLDINGS INC (CLVR) is expected to grow by 29.03% in the next year.